THE NEURONAL TOXIC FACTOR IN SERUM OF TYPE-1 DIABETIC-PATIENTS IS A COMPLEMENT-FIXING AUTOANTIBODY

被引：24
作者：
PITTENGER, GL
LIU, D
VINIK, AI
机构：
[1] The Diabetes Institutes, Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, Virginia
[2] Department of Anatomy and Neurobiology, Eastern Virginia Medical School, Norfolk, Virginia
来源：
DIABETIC MEDICINE | 1995年 / 12卷 / 05期
关键词：
DIABETES MELLITUS; AUTONOMIC NEUROPATHY; NEUROBLASTOMA; AUTOIMMUNITY; PATHOGENESIS;
D O I：
10.1111/j.1464-5491.1995.tb00499.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Type 1 diabetes is an autoimmune disease resulting in destruction of pancreatic beta cells. Many of the pancreatic beta cell autoantigens are also neuronal cell components. Using adrenergic neuroblastoma cells, we have previously demonstrated that humoral mechanisms may contribute to the development of diabetic neuropathy in Type 1 patients. We hypothesize that the toxic factor in Type 1 diabetic serum is an immunoglobulin. When neuroblastoma cells were exposed to immunoglobulins precipitated from serum of Type 1 diabetes patients with neuropathy, cell growth was significantly inhibited by day 5 (3.8 +/- 2.4 x 10(5) cells) compared to cells cultured with immunoglobulins from control (8.2 +/- 2.3 x 10(5) cells) or Type 2 diabetic serum (7.0 +/- 3.0 x 10(5) cells). The inhibitory effect (3.2 +/- 0.9 x 10(5) cells) could be removed from Type 1 diabetic serum by affinity precipitation with protein A-agarose (8.0 +/- 0.8 x 10(5) cells). Mild heat denaturing of the serum reversed the inhibitory effect (3.8 +/- 0.9 vs 1.4 +/- 1.4 x 10(5) cells), indicating a requirement for complement. Immunofluorescent labelling with anti-IgG secondary antibody of cells exposed to Type 1 diabetic serum indicated recognition of a membrane-bound antigen. The studies in this report support the hypothesis that autoimmune neuronal destruction may contribute to the development of diabetic autonomic neuropathy in patients with Type 1 diabetes.
引用
收藏
页码：380 / 386
页数：7
相关论文
共 36 条
  • [1] Vinik AI, Holland MT, LeBeau JM, Liuzzi FJ, Stansberry KB, Colen LB., Diabetic neuropathies, Diabetes Care, 15, pp. 1-50, (1992)
  • [2] Pittenger GL, Liu D., Vinik AI., The toxic effects of serum from patients with type I diabetes mellitus on mouse neuroblastoma cells: a new mechanism for development of autonomic neuropathy, Diabetic Med, 10, pp. 925-932, (1993)
  • [3] Freddo L., Ariga T., Latov N., The neuropathy of plasma cell dyscrasia: binding of IgM M‐proteins to peripheral nerve glycolipids, Neurology, 35, pp. 1420-1424, (1985)
  • [4] Freddo L., Yu RK, Latov N., Gangliosides GM1 and GD1b are antigens for IgM M‐protein in a patient with motor neuron disease, Neurology, 36, pp. 454-459, (1986)
  • [5] Latov N., Neuropathy and anti‐GM1 antibodies, Ann Neurol, 27, (1990)
  • [6] Quarles RH, Ilyas AA, Willison HJ., Serum antibodies to gangliosides in Guillain‐Barre syndrome, Ann Neurol, 27, (1990)
  • [7] Weng NP, Yu-lee L., Sanz I., Structure and specificities of anti‐ganglioside autoantibodies associated with motor neuropathies, J Immunol, 149, pp. 2518-2529, (1992)
  • [8] Van Doorn PA, Brand A., Strengers PWF, Meulstee J., Vermeulen M., High dose immunoglobulin (IVIg) treatment in chronic inflammatory demyelinating polyneuropathy: a double‐blind placebo‐controlled study, Neurology, 40, pp. 209-212, (1990)
  • [9] Haas DC, Tatum AH., Plasmapheresis alleviates neuropathy accompanying IgM anti‐myelin associated glycoprotein paraproteinemia, Ann Neurol, 23, pp. 394-396, (1988)
  • [10] Lundkvist I., Van Doorn PA, Vermeulen M., Brand A., Spontaneous recovery from the Guillain‐Barré syndrome is associated with anti‐idiotypic antibodies recognizing a cross‐reactive idiotype on anti‐neuroblastoma cell line antibodies, Clin Immunol Immunopathol, 67, pp. 192-198, (1993)
1234